← All Signals

🏥 FDA: Rising Pharma Holding, Inc. — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-03-20Date

Summary

Rising Pharma's Temozolomide Capsules recall due to stability testing failures indicates potential quality issues with their oncology product line. This could impact patient treatment continuity and trigger increased FDA scrutiny of their manufacturing processes.

Actionable: Monitor Rising Pharma's quality assurance measures and consider backup suppliers for Temozolomide.

AI Confidence: 80%

Data Points

firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now